These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26712103)

  • 1. Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.
    Wang H; Schabath MB; Liu Y; Stringfield O; Balagurunathan Y; Heine JJ; Eschrich SA; Ye Z; Gillies RJ
    Clin Lung Cancer; 2016 Jul; 17(4):271-8. PubMed ID: 26712103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
    Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.
    Liu Y; Kim J; Qu F; Liu S; Wang H; Balagurunathan Y; Ye Z; Gillies RJ
    Radiology; 2016 Jul; 280(1):271-80. PubMed ID: 26937803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semiquantitative Computed Tomography Characteristics for Lung Adenocarcinoma and Their Association With Lung Cancer Survival.
    Wang H; Schabath MB; Liu Y; Berglund AE; Bloom GC; Kim J; Stringfield O; Eikman EA; Klippenstein DL; Heine JJ; Eschrich SA; Ye Z; Gillies RJ
    Clin Lung Cancer; 2015 Nov; 16(6):e141-63. PubMed ID: 26077095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
    Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?
    Glynn C; Zakowski MF; Ginsberg MS
    J Thorac Oncol; 2010 Mar; 5(3):344-8. PubMed ID: 20087229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
    Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
    Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.
    Villaruz LC; Socinski MA; Cunningham DE; Chiosea SI; Burns TF; Siegfried JM; Dacic S
    Cancer; 2013 Jun; 119(12):2268-74. PubMed ID: 23526491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas.
    Lv J; Zhang H; Ma J; Ma Y; Gao G; Song Z; Yang Y
    Clin Radiol; 2018 Jun; 73(6):590.e1-590.e8. PubMed ID: 29454587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural retraction and intra-tumoral air-bronchogram as prognostic factors for stage I pulmonary adenocarcinoma following complete resection.
    Yoshino I; Nakanishi R; Kodate M; Osaki T; Hanagiri T; Takenoyama M; Yamashita T; Imoto H; Taga S; Yasumoto K
    Int Surg; 2000; 85(2):105-12. PubMed ID: 11071324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
    Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
    Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort.
    Mansuet-Lupo A; Bobbio A; Blons H; Becht E; Ouakrim H; Didelot A; Charpentier MC; Bain S; Marmey B; Bonjour P; Biton J; Cremer I; Dieu-Nosjean MC; Sautès-Fridman C; Régnard JF; Laurent-Puig P; Alifano M; Damotte D
    Chest; 2014 Sep; 146(3):633-643. PubMed ID: 24676429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
    Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
    Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.
    Yu HA; Sima CS; Shen R; Kass S; Gainor J; Shaw A; Hames M; Iams W; Aston J; Lovly CM; Horn L; Lydon C; Oxnard GR; Kris MG; Ladanyi M; Riely GJ
    J Thorac Oncol; 2015 Mar; 10(3):431-7. PubMed ID: 25415430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.
    Ziv E; Erinjeri JP; Yarmohammadi H; Boas FE; Petre EN; Gao S; Shady W; Sofocleous CT; Jones DR; Rudin CM; Solomon SB
    Radiology; 2017 Jan; 282(1):251-258. PubMed ID: 27440441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.